Efficacy and safety of PF-00299804 (PF299). an oral, irreversible, part-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC)

被引：17
|
作者：
Mok, T.
Spigel, D. R.
Park, K.
Socinski, M. A.
Tung, S. Y.
Kim, D.
Borzillo, G.
Zhang, H.
O'Connell, J. P.
Janne, P. A.
机构：
[1] Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China
[2] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[3] Sungkyunkwan Univ Sch Med, Samsung Med Ctr, Seoul, South Korea
[4] Univ N Carolina, Chapel Hill, NC USA
[5] Tuen Mun Hosp, Tuen Mun, Hong Kong, Peoples R China
[6] Seoul Natl Univ Hosp, Seoul 110744, South Korea
[7] Pfizer Inc, New London, CT USA
[8] Pfizer Res & Dev Co Ltd, Shanghai, Peoples R China
[9] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7537
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7537
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase 2 trial of PF-00299804 (PF299), an oral irreversible HER tyrosine kinase inhibitor (TKI), in patients (pts) with advanced NSCLC after failure of prior chemotherapy and erlotinib: preliminary efficacy and safety results
    Janne, Pasi A.
    Reckamp, Karen
    Koczywas, Marianna
    Camidge, David R.
    Engelman, Jeffery A.
    Khuri, Fadlo
    Rajan, Arun
    Gadgeel, Shirish
    Taylor, Ian
    Liang, Jane
    O'Connell, Joseph
    Giaccone, Giuseppe
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S293 - S294
  • [2] FIRST-LINE DACOMITINIB (PF-00299804), AN IRREVERSIBLE PAN-HER TYROSINE KINASE INHIBITOR, FOR PATIENTS WITH EGFR-MUTANT LUNG CANCERS
    Kris, M. G.
    Mok, T.
    Ou, S. -H. I.
    Martins, R. G.
    Kim, D. -W.
    Goldberg, Z.
    Zhang, H.
    Taylor, I.
    Letrent, S. P.
    Jaenne, P. A.
    ANNALS OF ONCOLOGY, 2012, 23 : 34 - 34
  • [3] First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers
    Kris, Mark G.
    Mok, Tony
    Ou, Sai-Hong Ignatius
    Martins, Renato
    Kim, Dong-Wan
    Goldberg, Zelanna
    Zhang, Hui
    Taylor, Ian
    Letrent, Stephen P.
    Janne, Pasi Antero
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] DACOMITINIB (PF-00299804), AN IRREVERSIBLE PAN-HER TYROSINE KINASE INHIBITOR (TKI), FOR FIRST-LINE TREATMENT OF EGFR-MUTANT OR HER2-MUTANT OR -AMPLIFIED LUNG CANCERS
    Kris, M.
    Goldberg, Z.
    Janne, P. A.
    Kim, D.
    Martins, R.
    Mok, T. S. K.
    O'Connell, J.
    Ou, S.
    Taylor, I.
    Zhang, H.
    ANNALS OF ONCOLOGY, 2012, 23 : 401 - 402
  • [5] A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib
    Reckamp, Karen L.
    Giaccone, Giuseppe
    Camidge, D. Ross
    Gadgeel, Shirish M.
    Khuri, Fadlo R.
    Engelman, Jeff A.
    Koczywas, Marianna
    Rajan, Arun
    Campbell, Alicyn K.
    Gernhardt, Diana
    Ruiz-Garcia, Ana
    Letrent, Stephen
    Liang, Jane
    Taylor, Ian
    O'Connell, Joseph P.
    Jaenne, Pasi A.
    CANCER, 2014, 120 (08) : 1145 - 1154
  • [6] EFFICACY AND SAFETY OF PF299804 AS FIRST-LINE TREATMENT (TX) OF PATIENTS (PTS) WITH ADVANCED (ADV) NSCLC SELECTED FOR ACTIVATING MUTATION (MU) OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)
    Mok, T.
    Spigel, D. R.
    Park, K.
    Socinski, M. A.
    Tung, S. Y.
    Kim, D-W
    Ou, S-H. I.
    Zhang, H.
    O'Connell, J. P.
    Jaenne, P.
    ANNALS OF ONCOLOGY, 2010, 21 : 8 - 8
  • [7] Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer
    Ramalingam, Suresh S.
    Blackhall, Fiona
    Krzakowski, Maciej
    Barrios, Carlos H.
    Park, Keunchil
    Bover, Isabel
    Heo, Dae Seog
    Rosell, Rafael
    Talbot, Denis C.
    Frank, Richard
    Letrent, Stephen P.
    Ruiz-Garcia, Ana
    Taylor, Ian
    Liang, Jane Q.
    Campbell, Alicyn K.
    O'Connell, Joseph
    Boyer, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27) : 3337 - 3344
  • [8] EFFICACY, SAFETY, AND PATIENT-REPORTED OUTCOMES OF FIRST-LINE DACOMITINIB (PF-00299804), AN IRREVERSIBLE PAN-HER TYROSINE KINASE INHIBITOR, IN PATIENTS WITH LUNG CANCERS HARBORING EGFR EXON 21 MUTATION OR EGFR EXON 19 DELETION
    Mok, Tony
    Kris, Mark G.
    Ou, Sai-hong I.
    Martins, Renato G.
    Kim, Dong-wan
    Goldberg, Zelanna
    Zhang, Hui
    Taylor, Ian
    O'Connell, Joseph
    Doherty, Jim
    Janne, Pasi A.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S453 - S453
  • [9] Personalizing Therapy in an Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Resistant Non-Small-Cell Lung Cancer Using PF-00299804 and Trastuzumab
    Kelly, Ronan J.
    Carter, Corey
    Giaccone, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (28) : E507 - E510
  • [10] Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).
    Siu, L. L.
    Hotte, S. J.
    Laurie, S. A.
    Singh, S.
    Winquist, E.
    Chia, S. K. L.
    Chen, E. X.
    Chan, K. K.
    Wang, T.
    Taylor, I.
    Ruiz-Garcia, A.
    Mormont, C.
    Soulieres, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345